STAT+: Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that all-too familiar routine of online calls and deadlines has returned. Moreover, there is anticipation over a looming FDA decision for a controversial Alzheimer’s drug. So time to get cracking and a brew a cup of stimulation, yes? Our choice today is butter pecan. Meanwhile, here are a few items of interest to help you on your journey. Hope all goes well today and you conquer the world. …

AstraZeneca (AZN) filed a lawsuit in the U.K. against GlaxoSmithKline (GSK), saying a 2012 licensing agreement over the Zejula cancer drug was breached and, therefore, it should have a greater share of sales, The Sunday Times reports. Glaxo acquired the medication, which is used to combat ovarian and other forms of cancer, as part of its $5 billion acquisition of Tesaro in late 2018. The drug generated $480 million in sales last year and was developed, in part, by technology owned by AstraZeneca and licensed to Glaxo.

Continue to STAT+ to read the full story…